A growing number of studies into pathways elucidating NK cell biology, activating and suppressing NK cell function, the development of pharmacological and genetic methods to enhance NK cell anti-tumor immunity, and the ability to expand NK cells ex vivo have set the stage for a new generation of cancer immunotherapies. As preclinical and clinical studies continue, there is a clear need to better understand the mechanisms underlying the regulation of NK cell phenotype and function within the tumor
environment to accelerate the development of NK cell-targeting therapeutics.
Cambridge Healthtech Institute’s 3rd Annual NK Cell-Based Cancer Immunotherapy conference will once again convene immuno-oncology researchers, cancer immunotherapy developers, and technology providers to discuss current challenges and opportunities
- from discovery NK immuno-oncology to clinical studies, share latest technologies and development approaches, as well as to provide updates on preclinical, clinical, and combination studies.
Engineering Pluripotent Cells for Off-the-Shelf Cancer Immunotherapy
Bahram (Bob) Valamehr, PhD, MBA, Vice President, Cancer Immunotherapy, Fate Therapeutics, Inc.
Strategies to Gain and Sustain Anti-Tumor Activity in NK Cell-Based Therapies
Evren Alici, MD, PhD, Head, Gene and Cell Therapy Group, Division of Hematology, Medicine, Karolinska University Hospital, Sweden
NKTR-255: Accessing the Immunotherapeutic Potential of IL-15 for NK Cell Therapies
Saul Kivimae, PhD, In Vivo Pharmacology Function Lead, Nektar Therapeutics
Clinical Updates on aNK and haNK Cells for Cancer Treatment
Hans Klingemann, MD, PhD, Vice President, Research & Development, NantKwest, Inc.
Complete Remission with Reduction of High-Risk Clones Following Haploidentical NK Cell Therapy against MDS and AML
Karl-Johan Malmberg, MD, PhD, Professor, Cancer Immunology, Institute for Cancer Research, Oslo University Hospital
Harnessing NK Cell Memory for Leukemia Immunotherapy
Rizwan Romee, MD, Faculty, Hematologic Oncology, Dana Farber Cancer Institute, Harvard Medical School
Tetravalent-Bispecific Immune Cell Engagers to Treat Hematological and Solid Cancers
Joachim Koch, PhD, Research Program Head, Affimed GmbH; Professor, Goethe-University Frankfurt
Phase I Study of Cord Blood-Derived Natural Killer Cells Combined with Autologous Stem Cell Transplantation in Multiple Myeloma
Katy Rezvani, MD, PhD, Professor, Stem Cell Transplantation, Cancer Medicine; Director, Translational Research, Internal Medicine, The University of Texas MD Anderson Cancer Center
Discovering Novel Therapeutic Antibody to Modulate NK Cells for Cancer Immunotherapy
Zhengmao Ye, PhD, Biochemical and Cellular Pharmacology, Genentech